{
    "clinical_study": {
        "@rank": "139426", 
        "acronym": "Pazotest-01", 
        "arm_group": {
            "arm_group_label": "Pazopanib", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive pazopanib at the dose of 800 mg/day orally until disease progression or evidence of unacceptable toxicity/side effects. The study will be performed according to Simon's two-stage optimal design."
        }, 
        "brief_summary": {
            "textblock": "This is an open label, single arm, single center, phase 2 study with the use of the\n      antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell\n      tumors who are not cured following first or subsequent chemotherapy lines for metastatic\n      disease, followed by eventual surgery."
        }, 
        "brief_title": "Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Germ Cell Tumors", 
            "Measurable Disease", 
            "Relapse or Progression After 2 or 3 Chemotherapy Regimens.", 
            "Relapse or Progression After High-dose Chemotherapy."
        ], 
        "condition_browse": {
            "mesh_term": [
                "Recurrence", 
                "Neoplasms, Germ Cell and Embryonal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male gender.\n\n          -  Confirmation of GCT histology based on pathologic review at Fondazione INT Milan.\n\n          -  Unequivocal progression of measurable disease.\n\n          -  A minimum of 2 and a maximum of 3 platinum-based chemotherapy lines for metastatic\n             disease.\n\n          -  First-line therapy should consist of at least 3 cycles of cisplatin-based\n             chemotherapy.\n\n          -  Prior single, tandem or triple high-dose chemotherapy course given as front-line or\n             salvage therapy is allowed.\n\n        Exclusion Criteria:\n\n          -  Failure to meet any of the above inclusion criteria.\n\n          -  Concurrent treatment with other cytotoxic drugs or targeted therapies.\n\n          -  Prior radiation therapy within 14 days of trial start."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01743482", 
            "org_study_id": "INT123/12"
        }, 
        "intervention": {
            "arm_group_label": "Pazopanib", 
            "intervention_name": "Pazopanib", 
            "intervention_type": "Drug", 
            "other_name": "Votrient"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Testicular Cancer", 
            "Germ Cell Tumors", 
            "Salvage Therapy", 
            "Pazopanib"
        ], 
        "lastchanged_date": "December 4, 2012", 
        "location": {
            "contact": {
                "email": "andrea.necchi@istitutotumori.mi.it", 
                "last_name": "Andrea Necchi, MD", 
                "phone": "+39 02 2390 2402"
            }, 
            "facility": {
                "address": {
                    "city": "Milano", 
                    "country": "Italy", 
                    "state": "Mi", 
                    "zip": "20133"
                }, 
                "name": "Fondazione IRCCS Istituto Nazionale dei Tumori"
            }, 
            "investigator": [
                {
                    "last_name": "Patrizia Giannatempo, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Andrea Necchi, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Single-agent Pazopanib (Votrient\u00ae) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT).", 
        "overall_contact": {
            "email": "andrea.necchi@istitutotumori.mi.it", 
            "last_name": "Andrea Necchi, MD", 
            "phone": "+39-02-2390-2402"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the proportion of patients who are progression-free after 3 months of pazopanib.", 
            "measure": "Progression Free Survival", 
            "safety_issue": "No", 
            "time_frame": "3-months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01743482"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
            "investigator_full_name": "Andrea Necchi", 
            "investigator_title": "Faculty, Department of Medical Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety and tolerability of pazopanib according to the Common Terminology Criteria for Adverse Events version 4.03", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "A response rate will be considered as the sum of complete (CR) and partial responses (PR) according to the response evaluation criteria in solid tumors (RECIST), version 1.1", 
                "measure": "Response Rate", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "OS time will be calculated as the interval from treatment start date to the date of death for any cause, with censoring at the date of last contact for patients alive. The Kaplan-Meier method will be used to estimate the OS curve.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}